Bio Products La Patent-Cliff Exposure & CMS Drug Spending Portfolio

Bio Products La (US): 4 reconciled FDA prescription therapies, $363.9M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$363.9M
2024 Medicare Part D Spend$295.8M
2024 Medicaid Spend$68.1M
California HCAI SB 17 Filings6 WAC filings (max 16.4% 2-yr change)